ICON Commercialization & Outcomes (ICO) optimizes the value of drugs and medical devices through innovative strategies and tactics that reflect evolving evidentiary, regulatory, and reimbursement requirements.

Enables secure real-time document review, co-authoring, and redaction in order to shorten the document review process by up to 65%.

Streamline clinical trial data capture through eSource workflows that support both Direct Data Capture and automated EHR-to-EDC data transfer across Paradigm Health’s research-ready provider network.

Research teams can capture study data within the EHR or through a standalone application, enabling consistent workflows across sites while reducing manual transcription. Sponsors gain faster access to cleaner trial data with fewer queries and more efficient monitoring.

More than just an electronic data collection tool, our robust clinical data management system combines an intuitive user interface, seamless online and offline data capture capabilities, and comprehensive data management for clinical trials in a single solution.

Elevate Your Clinical Research Data Collection

With ParexelAI™, you're not just optimizing your current development timeline, you're unlocking the ability to run more programs simultaneously across our global network and compress critical timelines. In a landscape where speed to market directly impacts patient outcomes, ParexelAI empowers you to innovate and make a meaningful difference in patients' lives.

Navigating drug safety in the era of innovation-driven medicine

The focus on drug safety and pharmacovigilance has never been more intense. Patient safety remains paramount throughout a product's lifecycle, even as sponsors and marketing authorization holders (MAHs) face increasing complexity in managing safety data. This complexity stems from huge volumes of data generated from scores of diverse sources, much of it rapidly expanding unstructured data. Innovation-driven medicine is a key factor. These dynamics are reshaping the landscape of drug safety, presenting both challenges and opportunities for innovation in pharmacovigilance practices.

The Australian Advantage is about saving time and minimizing costs while generating internationally accepted data in preparation for the next Phase.